Table of Contents
Cell and gene therapy doses can cost anywhere from several hundred thousand to over US$3 million each, with manufacturing alone accounting for as much as 70% of the price tag.
Cell and gene therapy manufacturing still runs largely on paper records and disconnected spreadsheets, and unlike a recalled small molecule, a single batch failure on a personalised therapy can cost a patient their life.
Autolomous's autoloMATE platform brings the full manufacturing journey for advanced therapies onto a single digital ecosystem, replacing siloed records with structured, audit-ready data that scales from discovery through commercial production. Founded in 2019, the London-based company now serves 22 clients worldwide – heavily concentrated in the US – and is extending the platform beyond cell and gene therapy into broader biopharma and life sciences. CEO Alexander Seyf argues the industry has to build the digital foundation first, because without it, the AI and robotisation everyone is now excited about have no data to act on.
At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Alexander Seyf to find out more.
A special thanks to our Onyx Live sponsors:
Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/
Comments